Pancreatic Cancer Research

ResearcherYonsei UniversityActive in the last 2 years

Sung Ill Jang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-4937-6167; OpenAlex author ID A5025219406, A5153456789. Sources: OpenAlex.

Their work

Papers
18 (first author 3, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
42
Papers, trials and grants by year

2015: 1 paper · 2016: none · 2017: none · 2018: none · 2019: none · 2020: none · 2021: 2 papers · 2022: 4 papers · 2023: 4 papers · 2024: 2 papers · 2025: 2 papers · 2026: 3 papers

Papers 18

  1. REG4 serves as a prognostic biomarker for pancreatic cancer with long-standing diabetes mellitus by modulating chemoresistance. Co-author DOI 10.1016/j.tranon.2026.102888↗
  2. FOLFIRINOX vs. gemcitabine/nab-paclitaxel for metastatic pancreatic cancer: A real-world study. Co-author DOI 10.1016/j.tranon.2026.103085↗
  3. Disulfiram/Copper Complex Induces Cytotoxicity in Pancreatic Cancer Cells and 5-Fluorouracil-Resistant Cells through Nuclear Factor E2-Related Factor-2 Suppres… Co-author DOI 10.5009/gnl250028↗
  4. Early prediction of liver metastasis in pancreatic cancer using routine clinical data: an externally validated machine learning model. Co-author DOI 10.1186/s12885-025-15285-4↗
  5. A New Staining Method Using Methionyl-tRNA Synthetase 1 Antibody for Endoscopic Ultrasound-Guided Fine-Needle Aspiration Cytology of Pancreatic Cancer. Co-author DOI 10.3390/diagnostics15141783↗
  6. Tumour-associated myeloid cells expressing IL-10R2/IL-22R1 as a potential biomarker for diagnosis and recurrence of pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41416-024-02676-w↗
  7. Survival predictors in patients with pancreatic cancer on liposomal irinotecan plus fluorouracil/leucovorin: a multicenter observational study. Co-author DOI 10.1177/17588359241279688↗
  8. Development of a metabolite calculator for diagnosis of pancreatic cancer. Co-author DOI 10.1002/cam4.6233↗
  9. Improved predictability of pancreatic ductal adenocarcinoma diagnosis using a blood immune cell biomarker panel developed from bulk mRNA sequencing and single-… Co-author DOI 10.1007/s00262-023-03458-8↗
  10. Prediction of Prognosis in Pancreatic Cancer According to Methionyl-tRNA Synthetase 1 Expression as Determined by Immunohistochemical Staining. Co-author DOI 10.3390/cancers15225413↗
  11. Prognostic Impact of Minimal Pelvic Fluid in Locally Advanced Pancreatic Cancer: A Multicenter Retrospective Study. Last author DOI 10.5152/tjg.2023.23309↗
  12. Identification of circulating myeloid cells as a potential diagnosis and recurrence marker of pancreatic ductal adenocarcinoma through the single-cell analysis Co-author DOI 10.21203/rs.3.rs-2345667/v1↗
  13. BRCA 1/2 Germline Mutation Predicts the Treatment Response of FOLFIRINOX with Pancreatic Ductal Adenocarcinoma in Korean Patients. Co-author DOI 10.3390/cancers14010236↗
  14. Validation of IL-7R as an Immunological Biomarker for Human Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers14030853↗
  15. The role of Jagged1 as a dynamic switch of cancer cell plasticity in PDAC assembloids. Co-author DOI 10.7150/thno.71364↗
  16. Cancer-initiating cells in human pancreatic cancer organoids are maintained by interactions with endothelial cells. First author DOI 10.1016/j.canlet.2020.10.012↗
  17. Characterization of Circulating IL-7R Positive Cell Populations for Early Detection of Pancreatic Ductal Adenocarcinoma. First author DOI 10.3390/jcm10184157↗
  18. Molecular mechanism of local drug delivery with Paclitaxel-eluting membranes in biliary and pancreatic cancer: new application for an old drug. First author DOI 10.1155/2015/568981↗

Closest collaborators

The 25 strongest of 42 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jae Hee Cho · 10 shared papers, 2022–2026 · strength 1.92
  2. Jung Hyun Jo · 6 shared papers, 2022–2026 · strength 1.36
  3. Dong Ki Lee · 8 shared papers, 2021–2025 · strength 1.36
  4. Joon Seong Park · 6 shared papers, 2021–2024 · strength 0.95
  5. Moon Jae Chung · 4 shared papers, 2022–2026 · strength 0.80
  6. Jeong Youp Park · 4 shared papers, 2022–2026 · strength 0.80
  7. Hyung Keun Lee · 5 shared papers, 2021–2024 · strength 0.78
  8. Eun‐Ju Chang · 4 shared papers, 2021–2024 · strength 0.63
  9. Jong‐Baeck Lim · 3 shared papers, 2021–2026 · strength 0.58
  10. Hee Seung Lee · 3 shared papers, 2022–2025 · strength 0.53
  11. Seungmin Bang · 3 shared papers, 2022–2025 · strength 0.53
  12. Jee Hoon Kim · 2 shared papers, 2025–2026 · strength 0.47
  13. Jiyoung Keum · 2 shared papers, 2024–2025 · strength 0.38
  14. Kyung In Shin · 2 shared papers, 2024–2025 · strength 0.38
  15. Eun Kyoung Kim · 1 shared paper, 2026 · strength 0.33
  16. Seung Woo Park · 2 shared papers, 2022–2024 · strength 0.33
  17. Jae-Il Choi · 2 shared papers, 2021–2022 · strength 0.32
  18. Jae-Il Choi · 1 shared paper, 2026 · strength 0.26
  19. Jin Hong Lim · 1 shared paper, 2025 · strength 0.22
  20. Hyung Sun Kim · 1 shared paper, 2025 · strength 0.22
  21. Don Haeng Lee · 2 shared papers, 2015–2023 · strength 0.22
  22. Y.J. Ko · 1 shared paper, 2025 · strength 0.20
  23. Min Jung Lee · 1 shared paper, 2023 · strength 0.18
  24. Munseok Choi · 1 shared paper, 2023 · strength 0.18
  25. Sung Hwan Lee · 1 shared paper, 2023 · strength 0.18

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.